Cefixime in the treatment of patients with lower respiratory tract infections: Results of US clinical trials

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 373-390

  Quintiliani, Richard ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFALEXIN; CEFIXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; BACTERIUM ISOLATION; BRONCHITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA; ORAL DRUG ADMINISTRATION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0029947115     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80019-1     Document Type: Article

References (37)

1. Ellner JJ. Management of acute and chronic respiratory tract infections. Am J Med. 1988;85(Suppl 3A):2-5.
2. LaForce FM. Antibacterial therapy for lower respiratory tract infections in adults: A review. Clin Infect Dis. 1992;14(Suppl 2):233-237.
3. Liu C. Infections of large and small airways. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious Diseases - A Treatise of Infectious Processes. 5th ed. Philadelphia: JB Lippincott Company; 1994:341-349.
4. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34: 2075-2080.
5. Wallace RJ Jr, Steingrube VA, Nash DR, et al. BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjunction in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother. 1989;33:1845-1854.
6. Brook I. Direct and indirect pathogenicity of beta-lactamase-producing bacteria in mixed infections in children. Crit Rev Microbiol. 1989;16:161-180.
7. Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis. 1992;14:1119-1123.
8. Varaldo PE, Nicoletti G, Schito GC, et al. Circulation in Italy of beta-lactamase-producing strains within the major groups of bacterial pathogens. Eur J Epidemiol. 1990;6:287-292.
9. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990:531-535.
10. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106: 196-204.
11. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med. 1982; 97:18-21.
12. Tager I, Speizer FE. Role of infection in chronic bronchitis. NEJM. 1975;292: 563-571.
13. Bates JH. The role of infection during exacerbations of chronic bronchitis. Ann Intern Med. 1982;97:130-131.
14. Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med. 1987;82(Suppl 4A):154-163.
15. Manresa F, Blavia R, Martin R, et al. Antibiotics for exacerbations of chronic bronchitis. Lancet. 1987;2:394-395. Letter.
16. Dere WH. Acute bronchitis: Results of U.S. and European trials of antibiotic therapy. Am J Med. 1992;92(Suppl 6A):53S-57S.
17. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother. 1994;38:2419-2425.
18. Lehtonen L, Huovinen P. Susceptibility of respiratory tract pathogens in Finland to cefixime and nine other antimicrobial agents. Scand J Infect Dis. 1993;25: 373-378.
19. Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs. 1989;38: 524-550.
20. Baldwin DR, Andrews JM, Ashby JP, et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax. 1990;45: 401-402.
21. Faulkner RD, Bohaychuk W, Lane RA, et al. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 1988;21:787-794.
22. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther. 1988;44:540-545.
23. Drehobl M, Sahn S, Puopolo A, et al. A multicenter trial of cefixime and cefuroxime axetil in the treatment of acute LRTI. Infect Med. 1993;10(Suppl B):22-28.
24. Heinz G, Greene S, Haddow A, et al. Comparison of cefixime and cefaclor in acute LRTI: Two randomized studies. Infect Med. 1993;10(Suppl B):29-35.
25. Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med. 1988;85(Suppl 3A):6-13.
26. Verghese A, Roberson D, Kalbfleisch JH, Sarubbi F. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 1990;34:1041-1044.
27. Wallace RJ Jr, Brown BA, Stocks JM, et al. Comparison of cefixime and amoxicillin/clavulanic acid in LRTI. Infect Med. 1993;10(Suppl B):16-21.
28. Davies BI, Maesen FPV. Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in the Netherlands. Drugs. 1986;31(Suppl 3):28-33.
29. Brook I. Direct and indirect pathogenicity of Branhamella catarrhalis. Drugs. 1986; 31(Suppl 3):97-102.
30. Yamada T, Yokota Y, Ikeda F, et al. Antibacterial activity of cefixime against Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae in the presence of Moraxella (Branhamella) catarrhalis. Chemotherapy (Japan). 1992; 38:28-35.
31. Rodriguez WJ, Schwartz RH, Akram S, Khan WN. Streptococcus pneumoniae resistant to penicillin: Incidence and potential therapeutic options. Laryngoscope. 1995;105:300-304.
32. Stefani S, Pellegrino MB, D'Amico G, et al. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae. Chemotherapy. 1992;38: 36-45.
33. Sanders CC. Beta-lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance. Antimicrob Agents Chemother. 1989;33:1313-1317.
34. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest. 1993;104: 1393-1399.
35. Beumer HM. Cefixime versus amoxicillin/clavulanic acid in lower respiratory tract infections. Int J Clin Pharmacol Ther Toxicol. 1989;27:30-33.
36. Wu DH. A review of the safety profile of cefixime. Clin Ther. 1993;15:1108-1119.
37. Tally FP, Desjardins RE, McCarthy EF, Cartwright K. Safety profile of cefixime. Pediatr Infect Dis J. 1987;6:976-980.